Cargando…

Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory

Coronavirus disease 2019 (COVID-19) is associated with extreme inflammatory response, disordered hemostasis and high thrombotic risk. A high incidence of thromboembolic events has been reported despite thromboprophylaxis, raising the question of a more effective anticoagulation. First-line hemostasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardy, M., Lecompte, T., Douxfils, J., Lessire, S., Dogné, J. M., Chatelain, B., Testa, S., Gouin-Thibault, I., Gruel, Y., Medcalf, R. L., ten Cate, H., Lippi, G., Mullier, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474970/
https://www.ncbi.nlm.nih.gov/pubmed/32922211
http://dx.doi.org/10.1186/s12959-020-00230-1
_version_ 1783579427232284672
author Hardy, M.
Lecompte, T.
Douxfils, J.
Lessire, S.
Dogné, J. M.
Chatelain, B.
Testa, S.
Gouin-Thibault, I.
Gruel, Y.
Medcalf, R. L.
ten Cate, H.
Lippi, G.
Mullier, F.
author_facet Hardy, M.
Lecompte, T.
Douxfils, J.
Lessire, S.
Dogné, J. M.
Chatelain, B.
Testa, S.
Gouin-Thibault, I.
Gruel, Y.
Medcalf, R. L.
ten Cate, H.
Lippi, G.
Mullier, F.
author_sort Hardy, M.
collection PubMed
description Coronavirus disease 2019 (COVID-19) is associated with extreme inflammatory response, disordered hemostasis and high thrombotic risk. A high incidence of thromboembolic events has been reported despite thromboprophylaxis, raising the question of a more effective anticoagulation. First-line hemostasis tests such as activated partial thromboplastin time, prothrombin time, fibrinogen and D-dimers are proposed for assessing thrombotic risk and monitoring hemostasis, but are vulnerable to many drawbacks affecting their reliability and clinical relevance. Specialized hemostasis-related tests (soluble fibrin complexes, tests assessing fibrinolytic capacity, viscoelastic tests, thrombin generation) may have an interest to assess the thrombotic risk associated with COVID-19. Another challenge for the hemostasis laboratory is the monitoring of heparin treatment, especially unfractionated heparin in the setting of an extreme inflammatory response. This review aimed at evaluating the role of hemostasis tests in the management of COVID-19 and discussing their main limitations.
format Online
Article
Text
id pubmed-7474970
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74749702020-09-08 Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory Hardy, M. Lecompte, T. Douxfils, J. Lessire, S. Dogné, J. M. Chatelain, B. Testa, S. Gouin-Thibault, I. Gruel, Y. Medcalf, R. L. ten Cate, H. Lippi, G. Mullier, F. Thromb J Review Coronavirus disease 2019 (COVID-19) is associated with extreme inflammatory response, disordered hemostasis and high thrombotic risk. A high incidence of thromboembolic events has been reported despite thromboprophylaxis, raising the question of a more effective anticoagulation. First-line hemostasis tests such as activated partial thromboplastin time, prothrombin time, fibrinogen and D-dimers are proposed for assessing thrombotic risk and monitoring hemostasis, but are vulnerable to many drawbacks affecting their reliability and clinical relevance. Specialized hemostasis-related tests (soluble fibrin complexes, tests assessing fibrinolytic capacity, viscoelastic tests, thrombin generation) may have an interest to assess the thrombotic risk associated with COVID-19. Another challenge for the hemostasis laboratory is the monitoring of heparin treatment, especially unfractionated heparin in the setting of an extreme inflammatory response. This review aimed at evaluating the role of hemostasis tests in the management of COVID-19 and discussing their main limitations. BioMed Central 2020-09-07 /pmc/articles/PMC7474970/ /pubmed/32922211 http://dx.doi.org/10.1186/s12959-020-00230-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Hardy, M.
Lecompte, T.
Douxfils, J.
Lessire, S.
Dogné, J. M.
Chatelain, B.
Testa, S.
Gouin-Thibault, I.
Gruel, Y.
Medcalf, R. L.
ten Cate, H.
Lippi, G.
Mullier, F.
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
title Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
title_full Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
title_fullStr Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
title_full_unstemmed Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
title_short Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
title_sort management of the thrombotic risk associated with covid-19: guidance for the hemostasis laboratory
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474970/
https://www.ncbi.nlm.nih.gov/pubmed/32922211
http://dx.doi.org/10.1186/s12959-020-00230-1
work_keys_str_mv AT hardym managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT lecomptet managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT douxfilsj managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT lessires managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT dognejm managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT chatelainb managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT testas managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT gouinthibaulti managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT gruely managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT medcalfrl managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT tencateh managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT lippig managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory
AT mullierf managementofthethromboticriskassociatedwithcovid19guidanceforthehemostasislaboratory